Full-Time

Scientist – Nonclinical Safety and Pathobiology

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$146.5k - $189.6k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Hybrid

Hybrid work: on-site in Foster City, CA; remote work not full-time.

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • Bachelor's Degree and Six Years' Experience OR Masters' Degree and Four Years' Experience
Responsibilities
  • Independently monitor and coordinate outsourced nonclinical safety studies supporting discovery, IND-enabling, and regulatory development programs, including test material planning, analytical testing coordination, shipment logistics, protocol development, dose level selection support, CRO communication, on-site study monitoring, data review, report review, and study archival.
  • Serve as lead study monitor for multi-study projects, developing study timelines, identifying critical path activities, troubleshooting formulation or test material issues, and driving timely resolution of operational and scientific questions.
  • Lead and coordinate internal and external study meetings with CRO study teams, project toxicologists, study monitors, analytical operations, bioanalytical/toxicokinetic partners, pathology, quality, regulatory, and other cross-functional stakeholders to support complex study logistics and timely execution.
  • Review protocols, amendments, raw data summaries, draft reports, final reports, and regulatory-supporting documents for scientific accuracy, internal consistency, compliance with study objectives, and alignment with Gilead expectations and style.
  • Coordinate report review cycles, prepare or support study result slides, compile tabulated study summaries, and assist project toxicologists with written or tabulated sections for regulatory documents such as INDs, NDAs, BLAs, and Investigator’s Brochures.
  • Perform independent QC review of study protocols, reports, SEND-related outputs, and regulatory submission documents to support high-quality, inspection-ready deliverables.
  • Apply expertise in GLP-regulated nonclinical studies, toxicology study conduct, animal welfare expectations, and regulatory guidance to identify risks, recommend solutions, and ensure studies are completed within established timelines.
  • Participate in CRO site selection, technical qualification visits, vendor oversight activities, study monitoring visits, and issue escalation as needed.
  • Support departmental initiatives, including SOP review, process improvement, harmonization of study templates and reporting practices, vendor oversight enhancements, and onboarding or mentoring of less experienced colleagues.
  • Serve as a technical resource or subject matter expert for standard nonclinical study designs, study logistics, CRO interactions, and study monitoring best practices.
  • Conduct scientific literature searches and apply findings to study planning, study interpretation, and regulatory support activities.
  • Travel as needed for CRO monitoring or qualification activities, typically less than 15%.
  • Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential. They ensure employees are receiving the feedback and insight needed to grow, develop and realize their purpose.
  • Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account. They provide the support needed to remove barriers and connect their team to the broader ecosystem
Desired Qualifications
  • BS or MS degree in toxicology, pharmacology, biology, physiology, veterinary sciences, or a related scientific discipline with significant pharmaceutical, biotechnology, or CRO industry experience
  • Direct experience independently monitoring GLP-regulated nonclinical safety studies, preferably across multiple study types, species, therapeutic areas, and modalities.
  • Strong understanding of toxicology principles, animal and human biology, physiology, study design, dose selection, toxicokinetics, pathology workflows, and nonclinical development requirements.
  • Working knowledge of Good Laboratory Practice regulations and relevant FDA, ICH, EMA, OECD, and other regulatory guidance governing nonclinical safety studies.
  • Knowledge of laboratory animal welfare standards, including USDA and AAALAC expectations, and familiarity with IACUC review processes.
  • Demonstrated ability to manage CRO relationships, coordinate multiple concurrent studies, anticipate risks, resolve study conduct or reporting issues, and maintain study timelines under tight deadlines.
  • Excellent written and verbal communication skills, including the ability to communicate complex study information clearly to scientific, operational, quality, and regulatory stakeholders.
  • Strong organizational skills, attention to detail, analytical thinking, sound judgment, and ability to work independently with a high level of logistical planning.
  • Proficiency with Microsoft Word, PowerPoint, and Excel; experience with study tracking systems, document management systems, SEND dataset review or visualization tools, and electronic QC workflows is preferred.
  • Membership or active participation in professional organizations such as ACT or SOT is encouraged.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $7.8 billion, led by HIV and Trodelvy.
  • Yeztugo PrEP sales surpassed $1 billion in Q2 2026, proving durable prevention demand.
  • California Supreme Court dismissed 23,000 HIV claims on August 3, removing litigation overhang.

What critics are saying

  • Biktarvy concentration exposes Gilead if ViiV or generics erode HIV share before 2036.
  • Veklury sales plunged 81% in Q2 2026, exposing dependence on shrinking pandemic revenue.
  • Anito-cel’s December 23, 2026 PDUFA is binary; rejection would weaken Gilead’s oncology expansion.

What makes Gilead Sciences unique

  • Biktarvy remains protected until April 1, 2036, anchoring Gilead’s HIV cash engine.
  • Gilead leads long-acting HIV prevention with Yeztugo, now available in 10 priority countries.
  • Its oncology mix combines Trodelvy, Yescarta, Tecartus, and anito-cel’s December 2026 launch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.

Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.

Ochre Digi Media Pvt. Ltd.
Aug 12th, 2026
Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration.

Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration. Wednesday, August 12, 2026 Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understanding tissue biology in its spatial context, AI-powered tissue analytics are becoming an essential component of biomarker discovery and translational research. Pharmaceutical companies are increasingly adopting approaches that integrate tissue architecture, biomarker expression, and clinical outcomes to accelerate therapeutic development. Nucleai's AI-native platform transforms routine pathology images into quantitative biological insights that accelerate biomarker discovery and support evidence-driven development decisions. As part of its collaboration with Gilead, Nucleai has analyzed a large dataset of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole-slide images across several clinical studies spanning multiple oncology indications, supporting Gilead's global ADC clinical development programs through advanced AI-driven tissue analytics integrated with clinical outcomes. The collaboration has generated novel biological insights and candidate spatial biomarkers for future scientific presentations and publications. The collaboration demonstrates how AI-powered Tissue Intelligence can standardize biomarker analyses while connecting tissue biology to clinical outcomes, creating a scalable foundation for translational research, biomarker development, and precision medicine. "Precision oncology is entering a new phase, where understanding tissue architecture is becoming just as important as understanding molecular alterations," said Avi Veidman, Chief Executive Officer of Nucleai. "Tissue Intelligence is becoming a foundational capability for precision medicine, helping identify the patients most likely to benefit while enabling pharmaceutical companies to translate tissue biology into reproducible biomarkers that improve the speed and success of oncology drug development." Unlike traditional image analysis approaches, Nucleai's AI-native platform integrates computational pathology, spatial biology, clinical outcomes, and multimodal data into a unified framework. This enables standardized biomarker assessment from preclinical research through late-stage clinical development while revealing mechanisms of response, resistance, and disease progression. The ongoing collaboration with Gilead and other leading pharmaceutical companies reflects growing industry recognition that AI-powered tissue analytics strengthen biomarker development and precision medicine across oncology portfolios. As target expression alone proves insufficient to explain ADC response, Nucleai's Tissue Intelligence platform integrates protein expression with tissue architecture, tumor heterogeneity, and microenvironmental context to better characterize the biological drivers of therapeutic efficacy. "Scale and reproducibility are becoming essential requirements for biomarker development," said Dr. Ken Bloom, Head of Pathology, Nucleai. "Our platform enables standardized spatial analyses across thousands of clinical samples while directly linking tissue biology to patient outcomes, generating evidence that can support translational research, biomarker qualification, and future companion diagnostic strategies." Nucleai continues to expand collaborations with leading pharmaceutical companies to advance biomarker discovery, translational medicine, companion diagnostic development, and AI-powered Tissue Intelligence across the oncology development lifecycle. About Nucleai Nucleai is a leader in AI-powered Tissue Intelligence, transforming pathology images into clinically actionable insights for pharmaceutical companies developing the next generation of precision medicines. By integrating computational pathology, spatial biology, multi-omics, and clinical data, Nucleai enables biomarker discovery, translational research, companion diagnostic development, and enterprise-scale AI-powered tissue analytics across the oncology development lifecycle. Contacts Media Contact Patrick Schmidt, Consort Partners [email protected]

Yahoo Finance
Aug 8th, 2026
Gilead raises 2026 outlook on HIV and PrEP strength, targets $30B in sales

Gilead Sciences reported second-quarter 2026 results that exceeded expectations, with revenues of $7.8 billion, up 10% year over year, and a non-GAAP loss per share of $6.75 beating consensus estimates. The company raised its full-year guidance for product sales excluding Veklury to $29.8 billion to $30.1 billion, an increase of $350 million at the midpoint. HIV sales drove growth, rising 12% in the quarter. Quarterly PrEP sales surpassed $1 billion for the first time, putting the prevention business at a $4 billion annual run rate. Gilead now expects full-year HIV sales to increase 9% to 10%, up from its prior 8% outlook. Biktarvy generated $3.8 billion in sales, whilst newer product Yeztugo delivered $232 million. The company maintained its approximately $1 billion full-year Yeztugo sales target, with more than 70% of users returning for reinjection at six months.